Business Model

 Adjuvantix operates a virtual business model with R&D, IP, accounting, legal and administration services all outsourced.  There are no fixed office or business leases.  This lean business model relies on working in alliance with world-class partners.  Many of these relationships are already in place and the Company is continuously seeking value-adding alliances in the vaccines R&D space.

ADX40-TB, ADX40-Prostate Cancer and ADX40-Lymphoma have been selected as product development opportunities that are secure commercial targets in their own right.  These programs are advancing in disease predictive models and key data are expected from the end of 2009 into 2010.

A key goal is to exemplify Adjuvantix' ADX40 as the adjuvant system of choice for partners and to provide robust proof of concept data that will promote further commercial alliances, licensing and exit opportunities.  Where appropriate, Adjuvantix will also seek third party collaborations for its ADX40 technology.

About Adjuvantix